CXCL9 expression promoter
A CXCL9 expression promoter using camellia extract addresses the challenge of senescent cell removal by enhancing CXCL9 expression, effectively improving skin health by targeting and eliminating these cells.
Patent Information
- Application Number
- JP2024013756
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-01-31
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2044-01-31
AI Technical Summary
Existing methods do not effectively promote the expression of CXCL9 to enhance the removal of senescent cells, which are associated with skin aging and related issues like wrinkles and age spots.
Development of a CXCL9 expression promoter containing camellia extract, which enhances CXCL9 expression in skin cells, particularly keratinocytes, to attract cytotoxic CD4-positive T lymphocytes that target and eliminate senescent cells.
The camellia extract-based CXCL9 promoter effectively promotes CXCL9 expression, leading to the removal of senescent cells and improving skin health by reducing wrinkles and age spots through apoptosis induction.
Smart Images

Figure 0007579470000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the development of a component that promotes the expression of CXCL9, which attracts cytotoxic CD4-positive T lymphocytes (CD4CTLs) involved in the elimination of senescent cells. [Background technology]
[0002] T cells that control immunity are broadly divided into CD4-positive T cells and CD8-positive T cells. CD4-positive T cells are called helper T cells that help the function of antibody-secreting B cells, and CD8-positive T cells are called killer T cells that kill virus-infected cells, cancer cells, and senescent cells with strong cytotoxic activity, and a method for enhancing these immune cells has been disclosed (Patent Document 1: JP2021-534829A). On the other hand, among CD4-positive T cells, there are T cells with cytotoxic activity, and such CD4-positive T cells are called cytotoxic CD4-positive T lymphocytes (CD4CTLs). It has been reported that cytotoxic CD4-positive cells express a group of genes expressed by CD8-positive T cells, and like CD8-positive T cells, they can kill virus-infected cells and tumor cells, and have been reported to have a high antitumor effect.
[0003] On the other hand, it has been reported that cytotoxic CD4-positive T lymphocytes act on senescent skin cells to induce apoptosis. It is believed that tissue homeostasis is maintained by the specific elimination of senescent cells by cytotoxic CD4-positive T lymphocytes. It has been reported that latent cytomegalovirus increases in senescent cells, and that cytotoxic CD4-positive T lymphocytes recognize senescent cells and induce apoptosis using membrane proteins produced by the influence of increased cytomegalovirus in the cells as a marker (Non-Patent Document 1: Cell 2023). The same document also identifies the importance of CXCL9 expression in attracting cytotoxic CD4-positive T lymphocytes to aged skin. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] Special Publication No. 2021-534829 [Non-patent literature]
[0005] [Non-Patent Document 1] Cell (2023) 186, 1417-1431 Summary of the Invention [Problem to be solved by the invention]
[0006] The objective of the present invention is to provide a method for maintaining healthy skin and ameliorating skin aging by promoting the removal of senescent cells in the skin. [Means for solving the problem]
[0007] The present inventors have been researching the development of products that improve skin aging, focusing on the system that removes senescent cells using cytotoxic CD4 positive cells. In the process, they focused on CXCL9, which plays an important role in attracting cytotoxic CD4 positive cells, and screened for ingredients that promote the expression of CXCL9. Surprisingly, they found camellia extract as an ingredient that promotes the expression of CXCL9 in the skin, which led to the present invention. Thus, the present invention relates to: [1-1] A CXCL9 expression promoter containing camellia extract. [1-2] Use of camellia extract for the manufacture of a CXCL9 expression promoter. [1-3] Camellia extract for use in inhibiting aging through promoting CXCL9 expression. [1-4] A method for suppressing CXCL9 expression in a subject suffering from an increased proportion of senescent cells, comprising administering a camellia extract. [2] The invention according to any one of Items 1-1 to 1-4, wherein the camellia extract is an extract extracted from a part selected from the group consisting of camellia seeds, flowers, leaves, and roots. [3] The invention according to item 2, wherein the camellia extract is a camellia seed extract or a fermented camellia seed extract. [4] The invention described in any one of Items 1-1 to 1-4 and 2 to 3, which is a skin topical preparation. [5] The invention described in any one of items 1-1 to 1-4 and 2 to 4, which promotes CXCL9 expression in keratinocytes. [6] A cosmetic method comprising applying a CXCL9 expression promoter described in any one of items 1-1 to 1-2 and items 2 to 5 subordinate thereto. Effect of the Invention
[0008] The Camellia extract selected according to the present invention can promote the expression of CXCL9 in skin cells. [Brief description of the drawings]
[0009] [Figure 1] Figure 1A shows the results of Western blotting indicating the change in CXCL9 expression in keratinocytes when camellia seed extract, camellia seed fermented extract, and their mixture were applied as candidate components, and Figure 1B is a graph showing the change in the relative expression level of CXCL9 to β-actin. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] One aspect of the present invention relates to a CXCL9 expression promoter comprising camellia extract. The CXCL9 expression promoter can be used as a food, cosmetic, or pharmaceutical product, and can exert an anti-aging effect through the removal of senescent cells. In addition, the CXCL9 expression promoter can exert any effect based on the induction of CXCR3-expressing cells, particularly cytotoxic CD4-positive cells.
[0011] CXCL9 is a chemokine belonging to the CXC chemokine family that induces cell migration. CXCL9 is expressed in epithelial cells and vascular endothelial cells as well as monocytes, and is secreted extracellularly. CXCL9 acts as a ligand for CXCR3, a chemokine receptor expressed by T cells, and is involved in the migration of cells expressing CXCR3. CXCL9 is also known to be induced by interferon-γ, and its expression increases mainly during inflammation, contributing to the attraction of lymphocytes to sites of infection and inflammation. It is also known to have antibacterial effects and to promote collagen production in fibroblasts.
[0012] In the present invention, the promotion of CXCL9 expression can be determined by the amount of CXCL9 protein and / or mRNA. The amount of CXCL9 protein in cells and / or secreted can be determined by an immunological method using an antibody that specifically binds to CXCL9. As an example, the amount of mRNA can also be measured by using PCR. The amount of mRNA can be measured by quantitative PCR or real-time PCR.
[0013] The expression promoter of CXCL9 can be called a secretion promoter of CXCL9. The expression and secretion of CXCL9 can enhance all or part of the effects induced by CXCL9. As an example, CXCR3-expressing cells can be attracted. Examples of CXCR3-expressing cells include CD4-positive T cells and CD8-positive T cells, NK cells, NKT cells, and some peripheral blood B cells, and among them, cytotoxic CD4-positive T lymphocytes are particularly noteworthy from the viewpoint of damaging senescent cells. Therefore, the expression promoter of CXCL9 can be called an attraction promoter of CXCR3-expressing cells, particularly cytotoxic CD4-positive cells, and an injury promoter of senescent cells. In addition, the expression promoter of CXCL9 can partially remove virus-infected cells and / or cancer cells through the attraction of cytotoxic CD4-positive cells, and can be called a therapeutic or preventive agent for viral infection, or a therapeutic or preventive agent for cancer.
[0014] The CXCL9 expression promoter can act on any cell that expresses CXCL9. Examples of cells that express CXCL9 include keratinocytes, monocytes, and vascular endothelial cells, but it is preferable to act on keratinocytes, especially from the viewpoint of acting percutaneously. The CXCL9 expression promoter applied percutaneously can penetrate the stratum corneum, granular layer, and spinous layer of the epidermis and act on keratinocytes present in the basal layer. CXCL9 secreted by acting on keratinocytes passes through the basement membrane and penetrates into the dermis layer, thereby attracting CXCR3-expressing cells to the dermis layer. Therefore, the CXCL9 expression promoter can also be said to be an inducer of CXCR3-expressing cells, especially cytotoxic CD4-positive cells. By acting percutaneously with the CXCL9 expression promoter, cytotoxic CD4-positive cells can be attracted to the skin, especially the dermis layer.
[0015] Among CXCR3-expressing cells, cytotoxic CD4-positive cells in particular can recognize senescent cells and induce apoptosis. Senescent cells include senescent dermal fibroblasts present in the dermis layer. Aged dermal fibroblasts cause wrinkles due to their slow division rate and low production capacity of interstitial components. In addition, senescent dermal fibroblasts are known to secrete aging factors such as IGFBP7, which can also have a negative effect on neighboring cells. Senescent cells highly express HLA-II and HCMV-glycoprotein B in association with human cytomegalovirus (HCMV) activation. Cytotoxic CD4-positive cells can specifically remove senescent cells through induction of apoptosis in a highly expressed HLA-II-dependent manner. Therefore, the expression promoter of CXCL9 can also be called a senescent cell remover. The expression promoter of CXCL9 can have an effect of improving skin troubles through the removal of senescent cells. In particular, since aged dermal fibroblasts cause age spots and wrinkles, removing aged dermal fibroblasts and promoting the proliferation of young dermal fibroblasts can prevent or improve aging. Examples of aging include skin aging, dermal fibroblast aging, wrinkles, and firmness improvement. Therefore, the CXCL9 expression promoter can also be called an aging improvement agent, particularly an improvement agent for skin aging, and an improvement agent for age spots, wrinkles, or firmness.
[0016] The route of administration of the CXCL9 expression promoter according to the present invention may be any route, including oral, transdermal, subcutaneous, intramuscular, intravenous, intraarterial, oral, and transmucosal administration. From the viewpoint of acting on the skin, transdermal or subcutaneous administration is particularly preferred. The transdermal or subcutaneously administered CXCL9 expression promoter acts on keratinocytes to promote secretion of CXCL9, and the secreted CXCL9 penetrates the dermal layer and promotes attraction of cytotoxic CD4+ T lymphocytes to the dermal layer, thereby exerting its effect.
[0017] The subject to which the CXCL9 expression promoter of the present invention is administered is a subject with an increased number of senescent cells or a subject with reduced expression of CXCL9 in the skin. Such a subject has symptoms associated with an increase in senescent cells. More specifically, such a subject suffers from symptoms associated with an increase in skin senescent cells, particularly skin aging such as spots, wrinkles, etc. The amount or proportion of skin senescent cells, particularly aged dermal fibroblasts, may be identified by a method well known in the art. The increase in skin senescent cells can be determined by determining the proportion of dermal fibroblasts that highly express HLA-II and / or HCMV-glycoprotein B from a skin sample. It is desirable to identify a subject with an increase in skin senescent cells and then administer the CXCL9 expression promoter of the present invention to such a subject.
[0018] A further aspect of the present invention may relate to a cosmetic method comprising applying a CXCL9 promoter. In such a cosmetic method, the CXCL9 promoter is applied to the skin of a subject having symptoms associated with skin aging cells, such as skin aging, wrinkles, and loss of elasticity. By applying the CXCL9 promoter to the skin, it becomes possible to remove the skin aging cells, and the skin aging cells are replaced with younger cells, thereby improving the symptoms associated with the skin aging cells. The cosmetic method according to the present invention is performed by a non-medical professional at a beauty salon or the like, and is not a therapeutic procedure, and can be called a non-therapeutic procedure.
[0019] In a further aspect of the present invention, the present invention also relates to a method for screening for a CXCL9 expression promoter or a skin aging inhibitor using the expression of the CXCL9 according to the present invention in keratinocytes as an index. More specifically, the screening method of the present invention comprises the following steps: Cultivating a culture comprising keratinocytes in a medium comprising the candidate component; Measuring the expression of CXCL9 in the cultured keratinocytes; and Comparing the measured CXCL9 expression level with that of a control. When the expression level of CXCL9 is enhanced, the candidate component can be screened as an agent for promoting the expression level of CXCL9. The control CXCL9 expression can be the expression of CXCL9 in keratinocytes cultured in a process that differs only in that it does not contain the candidate component. A control group may be a control group in which an experiment is performed in advance and a threshold value is set based on the CXCL9 expression in the control group, or the culture and measurement process may be performed in parallel. The CXCL9 expression level may be the amount of CXCL9 protein or mRNA in cultured keratinocytes, and can be measured using a method well known in the art, such as an immunological method or quantitative PCR, respectively.
[0020] Candidate components used in the screening method of the present invention can be any library of cosmetic materials, food materials, pharmaceutical materials, etc. Such libraries may include compound libraries, extract libraries, etc. The compounds and extracts contained in each library may be commercially available compounds and extracts, or may be synthesized compounds and prepared extracts.
[0021] The plant extracts described in this specification can be obtained by a conventional method, for example, by immersing or refluxing the plant with an extraction solvent at room temperature or at high temperature, followed by filtration and concentration. As the extraction solvent, any solvent that is usually used for extraction can be used, for example, aqueous solvents such as water, physiological saline, phosphate buffer, borate buffer, or organic solvents such as alcohols such as ethanol, propylene glycol, 1,3-butylene glycol, glycerin, hydrous alcohols, chloroform, dichloroethane, carbon tetrachloride, acetone, ethyl acetate, hexane, etc., can be used alone or in combination. Preferably, a mixed solvent of water and alcohol, such as 1,3-butylene glycol, is used as the solvent. The extract obtained by extraction with the above solvent can be used as it is, or the extract can be concentrated by, for example, freeze-drying, and if necessary, it can be used after removing impurities using an adsorption method, for example, an ion exchange resin, or after adsorption on a column of porous polymer (e.g., Amberlite XAD-2), eluted with a desired solvent, and further concentrated. The plant extract may be an extract commercially available as a cosmetic raw material, and the commercially available extract may be blended at a predetermined concentration.
[0022] Camellia extract is an extract obtained from the plant body of a plant belonging to the genus Camellia in the family Theaceae. In particular, it is an extract obtained from the seeds of Camellia or Camellia japonica. Camellia is native to Japan, but is widely distributed in the Japanese archipelago, as well as in the Korean peninsula, China, and Taiwan. Any part of the plant body of Camellia may be used, such as the tree, leaves, stems, flowers, seeds, and roots, but it can be extracted especially from camellia seeds. It may be extracted from the camellia seeds themselves, or it can be produced by further performing solvent extraction on the residue after squeezing camellia oil. Drying and / or powdering may be performed before extraction. In addition, the extract may be obtained by fermenting camellia seeds with microorganisms. The residue after squeezing camellia oil can be cultured, for example, with one of the four types of koji mold certified as national fungi, to obtain a camellia seed fermentation product. Examples of such koji mold include Aspergillus oryzae, which has the Japanese name yellow koji mold, Aspergillus sojae, which is classified as yellow koji mold (oryzae group), and white mutant strains of yellow koji mold; and (3) Aspergillus luchuensis (Aspergillus luchuensis var. awamori), which is classified as black koji mold, and white mutant strains of black koji mold, Aspergillus luchuensis mut. kawachii (Aspergillus kawachii). Camellia seed extract and fermented camellia seed extract are listed as follows in the display name used to display all ingredients in cosmetics as specified by the Japan Cosmetic Industry Association and the international display name according to the INCI name (International Nomenclature of Cosmetic Ingredients): Display name / INCI name: Camellia seed extract / CAMELLIA JAPONICA SEED EXTRACT, display name / INCI name: ASPERGILLUS / CAMELLIA JAPONICA SEED FERMENT EXTRACT FILTRATE. Solvent extract can be prepared by extracting with water, alcohol or a mixed solution thereof.As the alcohol, ethanol, glycerol, propylene glycol, or butylene glycol is used. More preferably, the extract can be extracted with a mixture of water and alcohol at any ratio, for example, a mixture of 10:90 to 90:10, preferably a mixture of 30:70 to 70:30, and more preferably a mixture of 50:50. More preferably, 1,3-butylene glycol can be used as the alcohol to be mixed with water. Camellia seed extract or camellia seed fermented extract is blended at a concentration of 0.001% to 1%, more preferably 0.01% to 0.1%. Camellia seed extract and camellia seed fermented extract may be mixed and blended at any ratio. For example, camellia seed extract and camellia seed fermented extract may be mixed at a ratio of 1:99 to 99:1, preferably 1:2 to 2:1, and more preferably 1:1. Camellia extract promotes CXCL9 expression.
[0023] The concentration and dosage form of the CXCL9 expression promoter of the present invention can be selected arbitrarily from the viewpoint of causing the desired effect, i.e., prevention of skin aging or improvement of wrinkles. Camellia extract, which is a CXCL9 expression promoter, can be incorporated into food, cosmetics, medicines, or quasi-drugs. When incorporated into food, it may be incorporated into nutritional supplements such as supplements and nutritional drinks, or functional food. When incorporated into cosmetics, it may be incorporated into face or body cosmetics such as lotions, milky lotions, beauty essences, creams, lotions, packs, essences, gels, etc., makeup cosmetics such as foundations, makeup bases, and concealers, and even bath additives. When incorporated into medicines, it may be administered orally or parenterally, for example, transdermally. When administered transdermally, it can be formulated into a skin topical agent. By using cosmetics, foods, medicines, and quasi-drugs containing the CXCL9 expression promoter, senescent cells are removed through the promotion of CXCL9 expression, and thus the aging inhibitory effect is exerted. The CXCL9 expression promoter can be administered for a long period of time as the food, cosmetics, or medicine of the present invention. From the viewpoint of exerting an anti-aging effect, the composition may be administered for several days or more, one week or more, two weeks or more, one month or more, three months or more, or six months or more. The upper limit is not particularly limited, but the composition may be administered for several years or less, for example, one year or less.
[0024] From the viewpoint of formulation in a skin external preparation, camellia seed extract or camellia seed fermented extract can be formulated as a CXCL9 expression promoter at 0.001% to 1%. From the viewpoint of fully exerting the effect, it can be formulated as a skin external preparation at preferably 0.01% or more, more preferably 0.1% or more. From the viewpoint of safety, it can be formulated at preferably 1% or less, more preferably 0.1% or less.
[0025] The skin topical preparation is not particularly limited as long as it is applicable to the skin, and any dosage form can be applied, for example, a solution, an emulsion, a solid, a semi-solid, a powder, a powder dispersion, a water-oil two-layer separation, a water-oil-powder three-layer separation, an ointment, a gel, an aerosol, a mousse, a stick, etc. When formulated into a skin topical preparation, a base and an excipient typically used in skin topical preparations, such as a preservative, an emulsifier, a pH adjuster, etc., may be used.
[0026] All documents mentioned herein are incorporated by reference in their entirety.
[0027] The following examples of the present invention are for illustrative purposes only and do not limit the technical scope of the present invention. The technical scope of the present invention is limited only by the claims. The present invention can be modified, for example, by adding, deleting, and replacing the constituent elements of the present invention, without departing from the spirit of the present invention. EXAMPLES
[0028] Example 1: Culture of human skin keratinocytes Human skin keratinocytes (Kurabo) were cultured at 5 × 10 4 Cells were seeded in 6-well plates at a concentration of 100 mM NaCl, incubated in KGM medium at 5% CO 2 The cells were cultured at 37°C for 2 days under atmospheric conditions. As candidate components, camellia seed extract (Yuka Sangyo) was added to the medium at 0.01% and fermented camellia seed extract was added at 0.1%, and the medium was cultured for 24 hours at 37°C. A control group, which differed only in that it did not contain the extract, was also cultured in the same way. After culturing, the cells were harvested, washed with PBS, and separated by SDS-PAGE. The gel was transferred to a PVDF membrane, and anti-CXCL9 antibody (Cell Signaling Technology) and anti-β-actin antibody (Santa Cruz) were used as the primary antibodies. Western blotting was performed using AP-labeled antibody (Thermo Fisher Scientific) as the secondary antibody. The results are shown in Figure 1. The expression of CXCL9 was enhanced when Camellia Seed Extract was added at 0.01% and when Camellia Fermented Seed Extract was added at 0.1%.
Claims
[Claim 1] A CXCL9 expression promoter comprising camellia seed extract, camellia seed fermented extract, or a mixture thereof, which promotes CXCL9 expression in keratinocytes.
Citation Information
Patent Citations
Antiinflammatory agent containing camellia plant extract
JP2014080409A
Composition and method for improving the appearance of aging hair
JP2015502406A
Stimulation of hair growth by senescent cells and senescence-associated secretory phenotypes
JP2020514395A
Single-chain chimeric polypeptides and uses thereof
JP2021534829A
Hydroalcoholic extract of camellia japonica and cosmetic compositions comprising the same
JP2022153335A
